Skip to main content

Resmed Value Stock - Dividend - Research Selection

Resmed

ISIN: US7611521078 , WKN: 895878

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures

2026-09-19
ResMed Inc. (NYSE:RMD) is well positioned to benefit from the long-term growth of the global obstructive sleep apnea (OSA) treatment market. Likewise, the company remains well positioned to benefit from growing awareness and penetration in the global market, backed by a robust product portfolio. The company’s OSA portfolio includes CPAP and APAP machines, led by […]

Dividend Champion, Contender, And Challenger Highlights: Week September 20

2026-09-18
Track weekly dividend updates for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend dates and pay dates here.

Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.

2026-09-15
Sleep device maker ResMed rose Tuesday after the stock notched an upgrade and price target increase on Wall Street. RBC Capital analysts boosted the stock’s rating to Outperform from Sector Perform on Tuesday, while lifting the price target to $262 from $244, citing growing demand for sleep apnea devices. The firm said that ResMed a top provider of devices for respiratory care and obstructive sleep apnea (OSA), is poised to gain market share as global awareness of the condition grows.

This Analyst Just Upgraded ResMed Stock. Here's Why.

2026-09-15
ResMed stock rallies on a bullish RBC Capital research note. Here’s why analyst Craig Wong-Pan raised his price target on RMD shares today.

Discover which S&P500 stocks are making waves on Tuesday.

2026-09-15
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.

RBC Capital Upgrades ResMed to Outperform from Sector Perform

2026-09-15

Is Margin Pressure From Rising Costs Altering The Investment Case For ResMed (RMD)?

2026-09-15
Earlier this year, ResMed reported quarterly results showing revenue of US$1.46 billion, up 8.6% year on year, with adjusted earnings per share ahead of expectations but accompanied by operating margin pressure from higher R&D and supply chain costs. Although the wider patient monitoring sector generally outperformed expectations, ResMed delivered the weakest revenue surprise and slowest growth among peers, raising questions about how rising expenses could affect its profitability...

ResMed Projected to Attain High-Single-Digit EPS Growth in Next Three Years, RBC Says

2026-09-15
ResMed (RMD) is projected to attain high-single-digit EPS growth over the next three years, despite

Wall Street Lunch: AI Regulation Hopes Fade After Trump Calls AI Concerns A 'Hoax'

2026-09-15
While AI companies may join together to pace the frontier, traders don’t think there is much chance of government regulation after President Trump pooh-poohed the idea of a robot revolution.

Is This the Right Time to Retain Resmed Stock in Your Portfolio?

2026-09-15
RMD's software portfolio optimization, mask innovation and solid financial health support growth, though macro pressures and competition pose risks.